A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Experts weigh in on the practical applications of PSMA PET imaging

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.